Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases

  • Calzaferri, Francesco
  • Ruiz Ruiz, Cristina
  • de Diego, Antonio M.G.
  • de Pascual, Ricardo
  • Méndez López, Iago
  • Cano Abad, María Francisca
  • Maneu, Victoria
  • de los Ríos, Cristóbal
  • Gandía Juan, Luis
  • García García, Antonio
Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in Alzheimer's disease (AD) in which all proposed treatments investigated in murine models have failed during clinical trials (CTs). Thus, novel therapeutic strategies remain crucial. Neuroinflammation is a common pathogenic feature of NDDs. As purinergic P2X7 receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug targets for NDDs. Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their molecular structure and functions, as well as their role in inflammation. Then, we elaborate on research undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists. Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and retinal degeneration. Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs. Finally, we reviewed previous and ongoing CTs investigating compounds directed toward targets associated with NDDs; we propose that CTs with P2X7R antagonists should be initiated. Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs. A better pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD., We would like to acknowledge the support received from the EU Horizon 2020 Research and Innovation Programme under Maria Sklodowska-Curie Grant Agreement N. 766124. We would also like to thank the support received from the Ministerio de Economía y Competitividad (MINECO, Spain; grant SAF2016-78892-R to Luis Gandía and Antonio G. García) and Fundación Teófilo Hernando
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

P2x7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis

  • Ruiz-Ruiz, Cristina
  • Calzaferri, Francesco
  • García García, Antonio
This review focuses on the purinergic ionotropic receptor P2X7 (P2X7R) as a potential target for developing drugs that delay the onset and/or disease progression in patients with amyotrophic lateral sclerosis (ALS). Description of clinical and genetic ALS features is followed by an analysis of advantages and drawbacks of transgenic mouse models of disease based on mutations in a bunch of proteins, particularly Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein-43 (TDP-43), Fused in Sarcoma/Translocated in Sarcoma (FUS), and Chromosome 9 open reading frame 72 (C9orf72). Though of limited value, these models are however critical to study the proof of concept of new compounds, before reaching clinical trials. The authors also provide a description of ALS pathogenesis including protein aggregation, calcium-dependent excitotoxicity, dysfunction of calcium-binding proteins, ultrastructural mitochondrial alterations, disruption of mitochondrial calcium handling, and overproduction of reactive oxygen species (ROS). Understanding disease pathogenic pathways may ease the identification of new drug targets. Subsequently, neuroinflammation linked with P2X7Rs in ALS pathogenesis is described in order to understand the rationale of placing the use of P2X7R antagonists as a new therapeutic pharmacological approach to ALS. This is the basis for the hypothesis that a P2X7R blocker could mitigate the neuroinflammatory state, indirectly leading to neuroprotection and higher motoneuron survival in ALS patients., This project has received funding from: (1) the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 766124; (2) the Spanish Ministry of Science, Technology and Innovation SAF2016-78892R; and (3) Fundación Teófilo Hernando.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation

  • Calzaferri, Francesco
  • Narros-Fernández, Paloma
  • De Pascual, Ricardo
  • De Diego, Antonio M.G.
  • Nicke, Annette
  • Egea, Javier
  • García García, Antonio
  • De Los Ríos, Cristóbal
The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood-brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium dynamics in a human P2X7-expressing HEK293 cell line, two-electrode voltage-clamp recordings in Xenopus laevis oocytes, and in interleukin 1β release assays in mouse peritoneal macrophages. BBB permeability was assessed by parallel artificial membrane permeability assays and P-glycoprotein ATPase activity. Dichloroarylpurinylethanones featured a certain P2X7 blockade, being compound 6 (2-(6-chloro-9H-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), named ITH15004, the most potent, selective, and BBB-permeable antagonist. Compound 6 can be considered as a first non-nucleotide purine hit for future drug optimizations, This work has been supported by the following grants: EU Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie, Grant Agreement N. 766124 to AGG and AN, and Ministerio de Economía y Competitividad, Spain, Grant Number SAF2016-78892R to AGG; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID: 335447717, SFB 1328 (TP15) to A.N.; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Grant Numbers PI16/01041 and PI19/01724 (Cofunded by FEDER) to CdlR; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Grant Numbers PI16/00735 and PI19/00082 (Co-funded by FEDER) to J.E.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice

  • Beamer, Edward
  • Morgan, James
  • Alves, Mariana
  • Menendez Mendez, Aida
  • Morris, Gareth
  • Zimmer, Bela
  • Conte, Giorgia
  • De Diego García, Laura
  • Alarcon Vila, Cristina
  • Yiu Ng, Nico Ka
  • Madden, Stephen
  • Calzaferri, Francesco
  • de los Rios, Cristobal
  • Garcia, Antonio G
  • Hamacher, Michael
  • Dinkel, Klaus
  • Pelegrin, Pablo
  • Henshall, DC
  • Nicke, Annette
  • Engel, Tobias
Background and Purpose: Refractory status epilepticus is a clinical emergency associated with high mortality and morbidity. Increasing evidence suggests neuroinflammation contributes to the development of drug-refractoriness during status epilepticus. Here, we have determined the contribution of the ATP-gated P2X7 receptor, previously linked to inflammation and increased hyperexcitability, to drug refractory status epilepticus and its therapeutic potential. Experimental Approach: Status epilepticus was induced via a unilateral microinjection of kainic acid into the amygdala in adult mice. Severity of status epilepticus was compared in animals with overexpressing or knock-out of the P2X7 receptor, after inflammatory priming by pre-injection of bacterial lipopolysaccharide (LPS) and in mice treated with P2X7 receptor-targeting and anti-inflammatory drugs. Key Results: Mice overexpressing P2X7 receptors were unresponsive to several anticonvulsants (lorazepam, midazolam, phenytoin and carbamazepine) during status epilepticus. P2X7 receptor expression increased in microglia during status epilepticus, at times when responses to anticonvulsants were reduced. Overexpression of P2X7 receptors induced a pro-inflammatory phenotype in microglia during status epilepticus and the anti-inflammatory drug minocycline restored normal responses to anticonvulsants in mice overexpressing P2X7 receptors. Pretreatment of wild-type mice with LPS increased P2X7 receptor levels in the brain and reduced responsiveness to anticonvulsants during status epilepticus, which was overcome by either genetic deletion of P2X7 receptors or treatment with the P2X7 receptor antagonists, AFC-5128 or ITH15004. Conclusion and Implications: Our results demonstrate that P2X7 receptor-induced pro-inflammatory effects contribute to resistance to pharmacotherapy during status epilepticus. Therapies targeting P2X7 receptors could be novel adjunctive treatments for drug-refractory status epilepticus.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice

  • Alves, Mariana
  • Gil, Beatriz
  • Villegas-Salmerón, Javier
  • Salari, Valentina
  • Martins-Ferreira, Ricardo
  • Arribas Blázquez, Marina
  • Menéndez Méndez, Aida
  • Da Rosa Gerbatin, Rogerio
  • Smith, Jonathon
  • de Diego-Garcia, Laura
  • Conte, Giorgia
  • Sierra-Marquez, Juan
  • Merino-Serrais, Paula|||0000-0002-1842-9476
  • Mitra, Meghma
  • Fernandez Martin, Ana
  • Wang, Yitao
  • Kesavan, Jaideep
  • Melia, Ciara
  • Parras, Alberto
  • Beamer, Edward
  • Zimmer, Béla
  • Heiland, Mona
  • Cavanagh, Brenton
  • Parcianello Cipolat, Rafael|||0000-0002-0013-1153
  • Morgan, James
  • Teng, Xinchen
  • Prehn, Jochen H.M.
  • Fabene, Paolo F
  • Bertini, Giuseppe
  • Artalejo, Antonio R.
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Nicke, Annette
  • Olivos-Oré, Luis A.
  • Connolly, Niamh M.C.
  • Henshall, David C
  • Engel, Tobias|||0000-0001-9137-0637
Background: The purinergic ATP-gated P2X7 receptor (P2X7R) is increasingly recognized to contribute to pathological neuroinflammation and brain hyperexcitability. P2X7R expression has been shown to be increased in the brain, including both microglia and neurons, in experimental models of epilepsy and patients. To date, the cell type-specific downstream effects of P2X7Rs during seizures remain, however, incompletely understood. Methods: Effects of P2X7R signaling on seizures and epilepsy were analyzed in induced seizure models using male mice including the kainic acid model of status epilepticus and pentylenetetrazole model and in male and female mice in a genetic model of Dravet syndrome. RNA sequencing was used to analyze P2X7R downstream signaling during seizures. To investigate the cell type-specific role of the P2X7R during seizures and epilepsy, we generated mice lacking exon 2 of the P2rx7 gene in either microglia (P2rx7:Cx3cr1-Cre) or neurons (P2rx7:Thy-1-Cre). To investigate the protective potential of overexpressing P2X7R in GABAergic interneurons, P2X7Rs were overexpressed using adeno-associated virus transduction under the mDlx promoter. Results: RNA sequencing of hippocampal tissue from wild-type and P2X7R knock-out mice identified both glial and neuronal genes, in particular genes involved in GABAergic signaling, under the control of the P2X7R following seizures. Mice with deleted P2rx7 in microglia displayed less severe acute seizures and developed a milder form of epilepsy, and microglia displayed an anti-inflammatory molecular profile. In contrast, mice lacking P2rx7 in neurons showed a more severe seizure phenotype when compared to epileptic wild-type mice. Analysis of single-cell expression data revealed that human P2RX7 expression is elevated in the hippocampus of patients with temporal lobe epilepsy in excitatory and inhibitory neurons. Functional studies determined that GABAergic interneurons display increased responses to P2X7R activation in experimental epilepsy. Finally, we show that viral transduction of P2X7R in GABAergic interneurons protects against evoked and spontaneous seizures in experimental temporal lobe epilepsy and in mice lacking Scn1a, a model of Dravet syndrome. Conclusions: Our results suggest a dual and opposing action of P2X7R in epilepsy and suggest P2X7R overexpression in GABAergic interneurons as a novel therapeutic strategy for acquired and, possibly, genetic forms of epilepsy.
ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice

  • Alves, Mariana
  • Diego García, Laura de
  • Vegliante, Gloria
  • Moreno, Óscar
  • Gil, Beatriz
  • Ramos Cabrer, Pedro
  • Mitra, Meghma
  • Fernández Martín, Ana
  • Menendez Mendez, Aida
  • Wang, Yitao
  • et al.
Post-traumatic epilepsy (PTE) is one of the most common life-quality reducing consequences of traumatic brain injury (TBI). However, to date there are no pharmacological approaches to predict or to prevent the development of PTE. The P2X7 receptor (P2X7R) is a cationic ATP-dependent membrane channel that is expressed throughout the brain. While increasing evidence suggests a role for the P2X7R during seizures and epilepsy, it is unclear if changes in P2X7R expression can predict TBI-induced epilepsy development, and whether P2X7R antagonism can protect against long-lasting brain hyperexcitability caused by TBI. Our results demonstrate the antiepileptogenic potential of P2X7R antagonism to prevent TBI-induced epilepsy and indicate that P2X7R-based PET imaging may be a useful diagnostic tool to identify people at risk of developing PTE.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dual role of the P2X7 receptor in dendritic outgrowth during physiological and pathological brain development

  • Mut-Arbona, Paula
  • Huang, Lumei
  • Baranyi, Mária
  • Tod, Pál
  • Iring, András
  • Calzaferri, Francesco
  • Ríos, Cristobal de los
  • Sperlágh, Beáta
At high levels, extracellular ATP operates as a “danger” molecule under pathologic conditions through purinergic receptors, including the ionotropic P2X7 receptor (P2X7R). Its endogenous activation is associated with neurodevelopmental disorders; however, its function during early embryonic stages remains largely unclear. Our objective was to determine the role of P2X7R in the regulation of neuronal outgrowth. For this purpose, we performed Sholl analysis of dendritic branches on primary hippocampal neurons and in acute hippocampal slices from WT mice and mice with genetic deficiency or pharmacological blockade of P2X7R. Because abnormal dendritic branching is a hallmark of certain neurodevelopmental disorders, such as schizophrenia, a model of maternal immune activation (MIA)-induced schizophrenia, was used for further morphologic investigations. Subsequently, we studied MIA-induced behavioral deficits in young adult mice females and males. Genetic deficiency or pharmacological blockade of P2X7R led to branching deficits under physiological conditions. Moreover, pathologic activation of the receptor led to deficits in dendritic outgrowth on primary neurons from WT mice but not those from P2X7R KO mice exposed to MIA. Likewise, only MIA-exposed WT mice displayed schizophrenia-like behavioral and cognitive deficits. Therefore, we conclude that P2X7R has different roles in the development of hippocampal dendritic arborization under physiological and pathologic conditions., This work was supported by Hungarian Research and Development Fund Grant 131629 to B.S.; Hungarian Brain Research Program Grant NAP2022-I-1/2022 to B.S.; Recovery and Resilience Facility of the European Union within the framework of Program Széchenyi Plan Plus Grant RRF-2.3.1-21-2022-00011, National Laboratory of Translational Neuroscience, and Grant RRF-2.3.1-21-2022-00015, National Laboratory of Drug Research and Development to B.S.; Post-Covid Program of the Hungarian Academy of Sciences Grant PC-II-2/2022 to B.S.; European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska Curie Grant Agreement 766124 to P.M.-A. and B.S.; and Hungarian Academy of Sciences Premium Postdoctoral Research Program PPD2019-20/2019-439 to A.I. We thank the Microscopy Center, Cell Biology Center, and Behavior Unit of IEM for support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

P2 receptor-mediated signaling in the physiological and pathological brain: from development to aging and diseas

  • Mut-Arbona, Paula
  • Sperlágh, Beáta
The purinergic pathway mediates both pro-inflammatory and anti-inflammatory responses, whereas the breakdown of adenosine triphosphate (ATP) is in a critical equilibrium. Under physiological conditions, extracellular ATP is maintained at a nanomolar concentration. Whether released into the medium following tissue damage, inflammation, or hypoxia, ATP is considered a clear indicator of cell damage and a marker of pathological conditions. In this overview, we provide an update on the participation of P2 receptor-mediated purinergic signaling in normal and pathological brain development, with special emphasis on neurodevelopmental psychiatric disorders. Since purinergic signaling is ubiquitous, it is not surprising that it plays a prominent role in developmental processes and pathological alterations. The main aim of this review is to conceptualize the time-dependent dynamic changes in the participation of different players in the purinome in shaping the normal and aberrant developmental patterns and diseases of the central nervous system over one's lifespan. This article is part of the Special Issue on "Purinergic Signaling: 50 years"., This work was supported by the Hungarian Research and Development Fund [grant number 131629 to B.S.], the Hungarian Brain Research Program [grant number NAP2022-I-1/2022 to B.S.], the Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus [grant number RRF-2.3.1-21-2022-00011, National Laboratory of Translational Neuroscience and grant number RRF-2.3.1-21-2022-00015, National Laboratory of Drug Research and Development to B.S.], and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska Curie grant [grant agreement number 766124 to P.M.A and B.S.].
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases

  • Calzaferri, Francesco
  • Ruiz‐Ruiz, Cristina
  • Diego, Antonio M. G. de
  • Pascual, Ricardo de
  • Méndez‐López, Iago
  • Cano‐Abad, María F.
  • Maneu, Victoria
  • Ríos, Cristóbal de los
  • Gandía Juan, Luis
  • García, Antonio G.
  • Maneu, Victoria|||/items/4619afed-7005-432f-96ee-e192fd5bfbe4
Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in Alzheimer's disease (AD) in which all proposed treatments investigated in murine models have failed during clinical trials (CTs). Thus, novel therapeutic strategies remain crucial. Neuroinflammation is a common pathogenic feature of NDDs. As purinergic P2X7 receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug targets for NDDs. Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their molecular structure and functions, as well as their role in inflammation. Then, we elaborate on research undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists. Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and retinal degeneration. Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs. Finally, we reviewed previous and ongoing CTs investigating compounds directed toward targets associated with NDDs; we propose that CTs with P2X7R antagonists should be initiated. Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs. A better pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Combined drug triads for synergic neuroprotection in retinal degeneration

  • Maneu, Victoria
  • Lax, Pedro
  • De Diego, Antonio Miguel G.
  • Cuenca, Nicolás
  • García, Antonio G.
  • Cuenca, Nicolás|||/items/9aff7e32-82c7-4c3b-9e61-c644ea7f9ec8
  • Lax, Pedro|||/items/4cc55375-3e6f-40f5-b3dc-8b55eb7dd8a7
  • Maneu, Victoria|||/items/4619afed-7005-432f-96ee-e192fd5bfbe4
This review focuses on retina degeneration occurring during glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP), and on the potential therapeutic use of triads of repositioned medicines, addressed to distinct but complementary targets, to prevent, delay or stop retina cell death. Although myriad pathogenic mechanisms have been implicated in these disorders, common signaling pathways leading to apoptotic cell death to all of them, and to all neurodegenerative diseases are (i) calcium dyshomeostasis/excitotoxicity; (ii) oxidative stress/mitochondrial dysfunction, and (iii) neuroinflammation/P2X7 receptor activation. From a therapeutic point of view, it is relevant to consider the multitarget approach based on the use of combined medicines acting on complementary pathogenic mechanisms that has been highly successful in the treatment of chronic diseases such as cancer, AIDS, pain, hypertension, Parkinson’s disease, cardiac failure, depression, or the epilepsies as the basic mechanisms of cell death do not differ between the different CNS degenerative diseases. We suggest the multi-target therapy approach could be more effective compared with single-drug treatments. Used at doses lower than standard, these triads may also be safer and more efficient. After the establishment of a proof-of-concept in animal models of retinal degeneration, potential successful preclinical trials of such combinations may eventually drive to test this concept in clinical trials in patients, first to evaluate the safety and efficacy of the drug combinations in humans and then their therapeutic advantages, if any, seeking the prevention and/or the delay of retina degeneration and blindness.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

MicroRNA-22 controls aberrant neurogenesis and changes in neuronal morphology after status epilepticus

  • Beamer, Edward H.
  • Jurado-Arjona, Jeronimo
  • Jimenez-Mateos, Eva M.
  • Morgan, James
  • Reschke, Cristina R.
  • Kenny, Aidan
  • de Leo, Gioacchino
  • Olivos-Oré, Luis A.
  • Arribas-Blázquez, Marina
  • Madden, Stephen F.
  • Merchán Rubira, Jesús
  • Delanty, Norman
  • Farrell, Michael A.
  • O’Brien, Donncha F.
  • Avila, Jesus
  • Diaz-Hernandez, Miguel
  • Miras-Portugal, M. Teresa
  • Rodríguez Artalejo, Antonio
  • Hernández Pérez, Félix
  • Henshall, David C.
  • Engel, Tobias
Prolonged seizures (status epilepticus, SE) may drive hippocampal dysfunction and epileptogenesis, at least partly, through an elevation in neurogenesis, dysregulation of migration and aberrant dendritic arborization of newly-formed neurons. MicroRNA-22 was recently found to protect against the development of epileptic foci, but the mechanisms remain incompletely understood. Here, we investigated the contribution of microRNA-22 to SE-induced aberrant adult neurogenesis. SE was induced by intraamygdala microinjection of kainic acid (KA) to model unilateral hippocampal neuropathology in mice. MicroRNA-22 expression was suppressed using specific oligonucleotide inhibitors (antagomir-22) and newly-formed neurons were visualized using the thymidine analog iodo-deoxyuridine (IdU) and a green fluorescent protein (GFP)-expressing retrovirus to visualize the dendritic tree and synaptic spines. Using this approach, we quantified differences in the rate of neurogenesis and migration, the structure of the apical dendritic tree and density and morphology of dendritic spines in newly-formed neurons.SE resulted in an increased rate of hippocampal neurogenesis, including within the undamaged contralateral dentate gyrus (DG). Newly-formed neurons underwent aberrant migration, both within the granule cell layer and into ectopic sites. Inhibition of microRNA-22 exacerbated these changes. The dendritic diameter and the density and average volume of dendritic spines were unaffected by SE, but these parameters were all elevated in mice in which microRNA-22 was suppressed. MicroRNA-22 inhibition also reduced the length and complexity of the dendritic tree, independently of SE. These data indicate that microRNA-22 is an important regulator of morphogenesis of newly-formed neurons in adults and plays a role in supressing aberrant neurogenesis associated with SE, This work was supported by funding from Science Foundation Ireland (13/SIRG/2098, 17/CDA/4708 and 16/TIDA/4059 to TE, 13/SIRG/2114 to EJ-M, 17/TIDA/5002 to CR, 13/IA/1891 and 16/RC/3948 to DH and co-funded under the European Regional Development Fund and by FutureNeuro Industry partners) from the Health Research Board (HRA-POR-2015-1243 to TE), from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement n◦ 602130 (to DH), from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to EB), from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (No 766124 to TE), S2013/ICE-2958 from Comunidad de Madrid to MM-P, from Fundación ‘‘La Caixa’’ to JM-R and from Areces Foundation C-XVIII and the Minister of Science and Universities of Spain BFU2014-53654-P to MM-P
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1 (G93A) female mice

  • Ruiz-Ruiz, Cristina
  • García-Magro, Nuria
  • Negredo Madrigal, Pilar
  • Avendaño Trueba, Carlos
  • Bhattacharya, Anindya
  • Ceusters, Marc
  • García García, Antonio
Neuroinflammation is one of the main physiopathological mechanisms of amyotrophic lateral sclerosis (ALS), produced by the chronic activation of microglia in the CNS. This process is triggered by the persistent activation of the ATP-gated P2X7 receptor (P2RX7, hereafter referred to as P2X7R). The present study aimed to evaluate the effects of the chronic treatment with the P2X7R antagonist JNJ-47965567 in the development and progression of ALS in the SOD1 murine model. SOD1 mice were intraperitoneally (i.p.) injected with either 30 mg/kg of JNJ-47965567 or vehicle 4 times per week, from pre-onset age (here, postnatal day 60; P60) until study endpoint. Body weight, motor coordination, phenotypic score, disease onset and survival were measured throughout the study, and compared between vehicle- and drug-injected groups. Treatment with the P2X7R antagonist JNJ-47965567 delayed disease onset, reduced body weight loss and improved motor coordination and phenotypic score in female SOD1 mice, although it did not increase lifespan. Interestingly, neither beneficial nor detrimental effects were observed in males in any of the analyzed parameters. Treatment did not affect motor neuron survival or ChAT, Iba-1 and P2X7R protein expression in endpoint individuals of mixed sexes. Overall, chronic administration of JNJ-47965567 for 4 times per week to SOD1 mice from pre-onset stage altered disease progression in female individuals while it did not have any effect in males. Our results suggest a partial, yet important, effect of P2X7R in the development and progression of ALS. G93A G93A G93A G93A, This project was supported by the European Union’s Horizon 2020 research and innovation programme under Marie Sklodowska-Curie grant agreement no. 766124; the Spanish Ministry of Science, Technology and Innovation (SAF2016-78892R); and Fundación Teófilo Hernando.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

  • Engel, Tobías
  • Gómez-Sintes, Raquel
  • Alves, Mariana
  • Jiménez-Mateos, Eva María
  • Fernández-Nogales, Marta
  • Sanz-Rodríguez, Amaya
  • Morgan, James
  • Beamer, Edward
  • Rodríguez-Matellán, Alberto G.
  • Dunleavy, Mark
  • Takanori, Sano
  • Ávila, Jesús
  • Medina, Miguel
  • Hernández Pérez, Félix
  • Lucas, José Javier
  • Henshall, David C.
14 p.-5 fig., Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3β isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases. Recent studies have also linked GSK-3 dysregulation to neuropathological outcomes in epilepsy. To date, however, there has been no genetic evidence for the involvement of GSK-3 in seizure-induced pathology. Status epilepticus (prolonged, damaging seizure) was induced via a microinjection of kainic acid into the amygdala of mice. Studies were conducted using two transgenic mouse lines: a neuron-specific GSK-3β overexpression and a neuron-specific dominant-negative GSK-3β (GSK-3β-DN) expression in order to determine the effects of increased or decreased GSK-3β activity, respectively, on seizures and attendant pathological changes in the hippocampus. GSK-3 inhibitors were also employed to support the genetic approach. Status epilepticus resulted in a spatiotemporal regulation of GSK-3 expression and activity in the hippocampus, with decreased GSK-3 activity evident in non-damaged hippocampal areas. Consistent with this, overexpression of GSK-3β exacerbated status epilepticus-induced neurodegeneration in mice. Surprisingly, decreasing GSK-3 activity, either via overexpression of GSK-3β-DN or through the use of specific GSK-3 inhibitors, also exacerbated hippocampal damage and increased seizure severity during status epilepticus. In conclusion, our results demonstrate that the brain has limited tolerance for modulation of GSK-3 activity in the setting of epileptic brain injury. These findings caution against targeting GSK-3 as a treatment strategy for epilepsy or other neurologic disorders where neuronal hyperexcitability is an underlying pathomechanism., This work was supported by funding from the Sixth Framework Programme (MIRG-CT-2004-014567, to D.C.H.) a IRCSET-Marie Curie International Mobility Fellowship, the Health Research Board (PD/2009/31 to T.E. and HRA_POR/ 2011/41 to D.C.H.); Science Foundation Ireland (13/SIRG/2098 and 17/CDA/ 4708 to T.E. and 16/RC/3948 to D.C.H.) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners;); from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to E.B.); from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklowdowska-Cuire grant agreement (No. 766124 to T.E.); grants from Ministerio de Economía Industria y Competitividad of Spain SAF2009-08233 and SAF2015-65371-R to J.J.L., SAF2016-78603-R to M.M. and BFU2016-77885-P to F.H.; grant PI2015-2/06-3 from CIBERNED-ISCIII to J.J.L.; and institutional grants to CBMSO from Fundación Ramón Areces and Fundación Banco de Santander., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The neurotoxic role of extracellular tau protein

  • Sebastián-Serrano, Álvaro
  • Diego-García, Laura de
  • Díaz-Hernández, Miguel
Tauopathies are a class of neurodegenerative diseases associated with the microtubule-associated protein tau, with Alzheimer's disease (AD) being the most prevalent related disorder. Neurofibrillary tangles (NFTs) are one of the neuropathological hallmarks present in the brains of AD patients. Because NFTs are aberrant intracellular inclusions formed by hyperphosphorylated tau, it was initially proposed that phosphorylated and/or aggregated intracellular tau protein was causative of neuronal death. However, recent studies suggest a toxic role for non-phosphorylated and non-aggregated tau when it is located in the brain extracellular space. In this work, we will discuss the neurotoxic role of extracellular tau as well its involvement in the spreading of tau pathologies., This work was supported by funding from the Spanish Ministry of Science and Education BFU2012-31195 European Union project H2020-MSCA-ITN-2017 number 766124 to M.D.-H. and from Universidad Complutense of Madrid (UCM)-Santander Central Hispano Bank PR41/17-21014 to M.D.-H. Á.S.-S. was hired by BFU2012-31195 grant and L.d.D.-G. has an UCM pre-doctoral fellowship supervised by M.D.-H., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Amyloid peptide induced neuroinflammation increases the P2X7 receptor expression in microglial cells, impacting on its functionality

  • Martínez-Frailes, Carlos
  • Di Lauro, Caterina
  • Bianchi, Carolina
  • Diego-García, Laura de
  • Sebastián-Serrano, Álvaro
  • Boscá, Lisardo
  • Díaz-Hernández, Miguel
© 2019 Martínez-Frailes, Di Lauro, Bianchi, de Diego-García, Sebastián-Serrano, Boscá and Díaz-Hernández., Alzheimer disease is a neurodegenerative disease characterized by the presence of senile plaques composed of amyloid-β (Aβ) peptide, neurofibrillary tangles, neuronal loss and neuroinflammation. Previous works have revealed that extracellular ATP, through its selective receptor P2X7 (P2X7R), is essential to neuroinflammation and neurotoxicity induced by Aβ. P2X7R is upregulated on microglial cells around the senile plaques. This upregulation progressively rises with age and is parallel with an accumulation of senile plaques and also correlates with the synaptic toxicity detected both in animal models reproducing AD and human patients of AD. Furthermore, the late onset of the first AD-associated symptoms suggests that aging associated-changes may be relevant to the disease progression. Thus, microglia motility and its capacity to respond to exogenous ATP stimulus decrease with aging. To evaluate whether the P2X7R age related-changes on microglia cells may be relevant to the AD progression, we generated a new transgenic mouse model crossing an Aβ peptide mouse model, J20 mice and the P2X7R reporter mice P2X7REGFP. Our results indicate that neuroinflammation induced by Aβ peptide causes changes in the P2X7R distribution pattern, increasing it s expression in microglial cells at advanced and late stages, when microgliosis occurs, but not in the early stages, in the absence of microgliosis. In addition, we found that P2X7R activation promotes microglial cells migration to senile plaques but decreases their phagocytic capacity. Moreover, we found a significant reduction of P2X7R transcription on neuronal cells at the early and advanced stages, but not at the late stages. Since previous studies have reported that either pharmacological inhibition or selective downregulation of P2X7R significantly improve behavioral alterations and reduce the incidence and size of senile plaques in the early and advanced stages of AD, the results presented here provide new evidence, indicating that this therapeutic approach could be also efficient in the late stages of the disease., This work was supported by funding from the Spanish Ministry of Science and Education BFU2012-31195 (to MD-H), SAF2017-82436R (to LB), European Union project H2020-MSCA-ITN-2017 number 766124 (to MD-H), and from Universidad Complutense of Madrid (UCM)-Santander Central Hispano Bank PR41/17-21014 (to MD-H). CM-F had an FPI pre-doctoral fellowship associated to BFU2012-31195. CDL and CB were hired by H2020-MSCA-ITN-2017 number 766124. AS-S was hired by BFU2012-31195 grant and LdD-G had an UCM pre-doctoral fellowship supervised by MD-H. This work was supported in part by FEDER.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CPEB4–CLOCK crosstalk during temporal lobe epilepsy

  • de Diego-Garcia, Laura
  • Brennan, Gary P
  • Auer, Theresa
  • Menendez-Mendez, Aida
  • Parras, Alberto
  • Martin-Gil, Alba
  • Mitra, Meghma
  • Ollà, Ivana
  • Villalba-Benito, Leticia
  • Gil, Beatriz
  • Alves, Mariana
  • Lau, Kelvin
  • Delanty, Norman
  • Beausang, Alan
  • Cryan, Jane
  • Brett, Francesca M.
  • Farrell, Michael A.
  • O'Brien, Donncha F.
  • Mendez, Raúl
  • Carracedo-Rodríguez, Gonzalo
  • Henshall, David C
  • Lucas, José J
  • Engel, Tobias
Objective: Posttranscriptional mechanisms are increasingly recognized as important contributors to the formation of hyperexcitable networks in epilepsy. Messenger RNA (mRNA) polyadenylation is a key regulatory mechanism governing protein expression by enhancing mRNA stability and translation. Previous studies have shown large-scale changes in mRNA polyadenylation in the hippocampus of mice during epilepsy development. The cytoplasmic polyadenylation element-binding protein CPEB4 was found to drive epilepsy-induced poly(A) tail changes, and mice lacking CPEB4 develop a more severe seizure and epilepsy phenotype. The mechanisms controlling CPEB4 function and the downstream pathways that influence the recurrence of spontaneous seizures in epilepsy remain poorly understood. Methods: Status epilepticus was induced in wild-type and CPEB4-deficient male mice via an intra-amygdala microinjection of kainic acid. CLOCK binding to the CPEB4 promoter was analyzed via chromatin immunoprecipitation assay and melatonin levels via high-performance liquid chromatography in plasma. Results: Here, we show increased binding of CLOCK to recognition sites in the CPEB4 promoter region during status epilepticus in mice and increased Cpeb4 mRNA levels in N2A cells overexpressing CLOCK. Bioinformatic analysis of CPEB4-dependent genes undergoing changes in their poly(A) tail during epilepsy found that genes involved in the regulation of circadian rhythms are particularly enriched. Clock transcripts displayed a longer poly(A) tail length in the hippocampus of mice post-status epilepticus and during epilepsy. Moreover, CLOCK expression was increased in the hippocampus in mice post-status epilepticus and during epilepsy, and in resected hippocampus and cortex of patients with drug-resistant temporal lobe epilepsy. Furthermore, CPEB4 is required for CLOCK expression after status epilepticus, with lower levels in CPEB4-deficient compared to wild-type mice. Last, CPEB4-deficient mice showed altered circadian function, including altered melatonin blood levels and altered clustering of spontaneous seizures during the day. Significance: Our results reveal a new positive transcriptional–translational feedback loop involving CPEB4 and CLOCK, which may contribute to the regulation of the sleep–wake cycle during epilepsy., H2020 Marie Skłodowska-Curie Actions, Grant/Award Number:766124 and 796600; Irish Research Council, Grant/Award Number:GOIPD/2020/806; Programa de Atracción de Talento de la Comunidad de Madrid, Grant/Award Number: 2020-T2/BMD- 20180; Science Foundation Ireland, Grant/Award Number:16/RC/3948 and 17/CDA/4708;Spanish Ministry of Economy and Competitiveness/Ministry of Science, Innovation and Universities, Grant/Award Number: PID2021- 123141OB- I00, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

P2 receptor-mediated signaling in the physiological and pathological brain: from development to aging and diseas

  • Mut-Arbona, Paula
  • Sperlágh, Beáta
The purinergic pathway mediates both pro-inflammatory and anti-inflammatory responses, whereas the breakdown of adenosine triphosphate (ATP) is in a critical equilibrium. Under physiological conditions, extracellular ATP is maintained at a nanomolar concentration. Whether released into the medium following tissue damage, inflammation, or hypoxia, ATP is considered a clear indicator of cell damage and a marker of pathological conditions. In this overview, we provide an update on the participation of P2 receptor-mediated purinergic signaling in normal and pathological brain development, with special emphasis on neurodevelopmental psychiatric disorders. Since purinergic signaling is ubiquitous, it is not surprising that it plays a prominent role in developmental processes and pathological alterations. The main aim of this review is to conceptualize the time-dependent dynamic changes in the participation of different players in the purinome in shaping the normal and aberrant developmental patterns and diseases of the central nervous system over one's lifespan. This article is part of the Special Issue on "Purinergic Signaling: 50 years"., This work was supported by the Hungarian Research and Development Fund [grant number 131629 to B.S.], the Hungarian Brain Research Program [grant number NAP2022-I-1/2022 to B.S.], the Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus [grant number RRF-2.3.1-21-2022-00011, National Laboratory of Translational Neuroscience and grant number RRF-2.3.1-21-2022-00015, National Laboratory of Drug Research and Development to B.S.], and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska Curie grant [grant agreement number 766124 to P.M.A and B.S.].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dual role of the P2X7 receptor in dendritic outgrowth during physiological and pathological brain development

  • Mut-Arbona, Paula
  • Huang, Lumei
  • Baranyi, Mária
  • Tod, Pál
  • Iring, András
  • Calzaferri, Francesco
  • Ríos, Cristobal de los
  • Sperlágh, Beáta
At high levels, extracellular ATP operates as a “danger” molecule under pathologic conditions through purinergic receptors, including the ionotropic P2X7 receptor (P2X7R). Its endogenous activation is associated with neurodevelopmental disorders; however, its function during early embryonic stages remains largely unclear. Our objective was to determine the role of P2X7R in the regulation of neuronal outgrowth. For this purpose, we performed Sholl analysis of dendritic branches on primary hippocampal neurons and in acute hippocampal slices from WT mice and mice with genetic deficiency or pharmacological blockade of P2X7R. Because abnormal dendritic branching is a hallmark of certain neurodevelopmental disorders, such as schizophrenia, a model of maternal immune activation (MIA)-induced schizophrenia, was used for further morphologic investigations. Subsequently, we studied MIA-induced behavioral deficits in young adult mice females and males. Genetic deficiency or pharmacological blockade of P2X7R led to branching deficits under physiological conditions. Moreover, pathologic activation of the receptor led to deficits in dendritic outgrowth on primary neurons from WT mice but not those from P2X7R KO mice exposed to MIA. Likewise, only MIA-exposed WT mice displayed schizophrenia-like behavioral and cognitive deficits. Therefore, we conclude that P2X7R has different roles in the development of hippocampal dendritic arborization under physiological and pathologic conditions., This work was supported by Hungarian Research and Development Fund Grant 131629 to B.S.; Hungarian Brain Research Program Grant NAP2022-I-1/2022 to B.S.; Recovery and Resilience Facility of the European Union within the framework of Program Széchenyi Plan Plus Grant RRF-2.3.1-21-2022-00011, National Laboratory of Translational Neuroscience, and Grant RRF-2.3.1-21-2022-00015, National Laboratory of Drug Research and Development to B.S.; Post-Covid Program of the Hungarian Academy of Sciences Grant PC-II-2/2022 to B.S.; European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska Curie Grant Agreement 766124 to P.M.-A. and B.S.; and Hungarian Academy of Sciences Premium Postdoctoral Research Program PPD2019-20/2019-439 to A.I. We thank the Microscopy Center, Cell Biology Center, and Behavior Unit of IEM for support.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice

  • Alves, Mariana
  • Gil, Beatriz
  • Villegas Salmerón, Javier
  • Salari, Valentina
  • Martins Ferreira, Ricardo
  • Arribas Blázquez, Marina
  • Menéndez Méndez, Aida
  • Da Rosa Gerbatin, Rogerio
  • Smith, Jonathon
  • De Diego García, Laura
  • Conte, Giorgia
  • Sierra Márquez, Juan
  • Merino Serrais, Paula
  • Mitra, Meghma
  • Fernández Martín, Ana
  • Wang, Yitao
  • Kesavan, Jaideep
  • Melia, Ciara
  • Parras, Alberto
  • Beamer, Edward
  • Zimmer, Béla
  • Heiland, Mona
  • Cavanagh, Brenton
  • Parcianello Cipolat, Rafael
  • Morgan, James
  • Teng, Xinchen
  • Rodríguez Artalejo, Antonio
  • Olivos Ore, Luis Alcides
  • Engel, Tobias
Background: The purinergic ATP-gated P2X7 receptor (P2X7R) is increasingly recognized to contribute to pathological neuroinflammation and brain hyperexcitability. P2X7R expression has been shown to be increased in the brain, including both microglia and neurons, in experimental models of epilepsy and patients. To date, the cell type-specific downstream effects of P2X7Rs during seizures remain, however, incompletely understood. Methods: Effects of P2X7R signaling on seizures and epilepsy were analyzed in induced seizure models using male mice including the kainic acid model of status epilepticus and pentylenetetrazole model and in male and female mice in a genetic model of Dravet syndrome. RNA sequencing was used to analyze P2X7R downstream signaling during seizures. To investigate the cell type-specific role of the P2X7R during seizures and epilepsy, we generated mice lacking exon 2 of the P2rx7 gene in either microglia (P2rx7:Cx3cr1-Cre) or neurons (P2rx7:Thy-1-Cre). To investigate the protective potential of overexpressing P2X7R in GABAergic interneurons, P2X7Rs were overexpressed using adeno-associated virus transduction under the mDlx promoter. Results: RNA sequencing of hippocampal tissue from wild-type and P2X7R knock-out mice identified both glial and neuronal genes, in particular genes involved in GABAergic signaling, under the control of the P2X7R following seizures. Mice with deleted P2rx7 in microglia displayed less severe acute seizures and developed a milder form of epilepsy, and microglia displayed an anti-inflammatory molecular profile. In contrast, mice lacking P2rx7 in neurons showed a more severe seizure phenotype when compared to epileptic wild-type mice. Analysis of single-cell expression data revealed that human P2RX7 expression is elevated in the hippocampus of patients with temporal lobe epilepsy in excitatory and inhibitory neurons. Functional studies determined that GABAergic interneurons display increased responses to P2X7R activation in experimental epilepsy. Finally, we show that viral transduction of P2X7R in GABAergic interneurons protects against evoked and spontaneous seizures in experimental temporal lobe epilepsy and in mice lacking Scn1a, a model of Dravet syndrome. Conclusions: Our results suggest a dual and opposing action of P2X7R in epilepsy and suggest P2X7R overexpression in GABAergic interneurons as a novel therapeutic strategy for acquired and, possibly, genetic forms of epilepsy.
Docta Complutense
Publicación Artículo científico (JournalArticle)

P2X7 Receptor-Dependent microRNA Expression Profile in the Brain Following Status Epilepticus in Mice

  • Conte, Giorgia
  • Nguyen, Ngoc T.
  • Alves, Mariana
  • De Diego García, Laura
  • Kenny, Aidan
  • Nicke, Annette
  • Henshall, David C.
  • Jimenez-Mateos, Eva M.
  • Engel, Tobias
The ionotropic ATP-gated P2X7 receptor is an important contributor to inflammatory signaling cascades via the release of Interleukin-1b, as well as having roles in cell death, neuronal plasticity and the release of neurotransmitters. Accordingly, there is interest in targeting the P2X7 receptor for the treatment of epilepsy. However, the signaling pathways downstream of P2X7 receptor activation remain incompletely understood. Notably, recent studies showed that P2X7 receptor expression is controlled, in part, by microRNAs (miRNAs). Here, we explored P2X7 receptor-dependent microRNA expression by comparing microRNA expression profiles of wild-type (wt) and P2X7 receptor knockout mice before and after status epilepticus. Genome-wide microRNA profiling was performed using hippocampi from wt and P2X7 receptor knockout mice following status epilepticus induced by intra-amygdala kainic acid. This revealed that the genetic deletion of the P2X7 receptor results in distinct patterns of microRNA expression. Specifically, we found that in vehicle-injected control mice, the lack of the P2X7 receptor resulted in the up-regulation of 50 microRNAs and down-regulation of 35 microRNAs. Post-status epilepticus, P2X7 receptor deficiency led to the up-regulation of 44 microRNAs while 13 microRNAs were down-regulated. Moreover, there was only limited overlap among identified P2X7 receptor-dependent microRNAs between control conditions and post-status epilepticus, suggesting that the P2X7 receptor regulates the expression of different microRNAs during normal physiology and pathology. Bioinformatic analysis revealed that genes targeted by P2X7 receptor-dependent microRNAs were particularly overrepresented in pathways involved in intracellular signaling, inflammation, and cell death; processes that have been repeatedly associated with P2X7 receptor activation. Moreover, whereas genes involved in signaling pathways and inflammation were common among up- and down-regulated P2X7 receptor-dependent microRNAs during physiological and pathological conditions, genes associated with cell death seemed to be restricted to up-regulated microRNAs during both physiological conditions and post-status epilepticus. Taken together, our results demonstrate that the P2X7 receptor impacts on the expression profile of microRNAs in the brain, thereby possibly contributing to both the maintenance of normal cellular homeostasis and pathological processes.
Docta Complutense
Publicación Artículo científico (JournalArticle)

TNAP and P2X7R: New Plasma Biomarkers for Alzheimer’s Disease

  • Aivar, Paloma
  • Bianchi, Carolina
  • Di Lauro, Caterina
  • Soria Tobar, Lucía
  • Álvarez Castelao, Beatriz
  • Calero, Miguel
  • Medina, Miguel
  • Díaz Hernández, Miguel
Over the last few years, intense research efforts have been made to anticipate or improve the diagnosis of Alzheimer’s disease by detecting blood biomarkers. However, the most promising blood biomarkers identified to date have some limitations, most of them related to the techniques required for their detection. Hence, new blood biomarkers should be identified to improve the diagnosis of AD, better discriminate between AD and mild cognitive impairment (MCI) and identify cognitively unimpaired (CU) older individuals at risk for progression to AD. Our previous studies demonstrated that both the purinergic receptor P2X7 and the tissue-nonspecific alkaline phosphatase ectoenzyme (TNAP) are upregulated in the brains of AD patients. Since both proteins are also present in plasma, we investigated whether plasma P2X7R and TNAP are altered in MCI and AD patients and, if so, their potential role as AD biomarkers. We found that AD but not MCI patients present increased plasma P2X7R levels. Nevertheless, TNAP plasma activity was increased in MCI patients and decreased in the AD group. ROC curve analysis indicated that measuring both parameters has a reasonable discriminating capability to diagnose MCI and AD conditions. In addition to confirming that individuals progressing to MCI have increased TNAP activity in plasma, longitudinal studies also revealed that CU individuals have lower plasma TNAP activity than stable controls. Thus, we propose that P2X7 and TNAP could serve as new plasma biomarkers for MCI and AD.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury.

  • Valencia, Inés
  • Pastor-Martínez, Andrea
  • Decouty-Pérez, Céline
  • Lopez-Rodriguez, Ana Belen
  • Álvarez-Rubal, María
  • Ramos Alonso, Eva
  • Calzaferri, Francesco
  • Zamorano-Fernández, Jorge
  • Giner-García, Javier
  • Palpán-Flores, Alexis J
  • Rodríguez-Domínguez, Víctor
  • Rodríguez de Cía, Javier
  • Hernández-García, Borja J
  • Romero Martínez, Manuel Alejandro
  • de Los Ríos, Cristóbal
  • Egea, Javier
Background and purpose: Traumatic brain injury (TBI) is considered to be a leading cause of mortality and disability worldwide. After TBI, innate immunity is rapidly activated in response to damage-associated molecular patterns, such as ATP release, recognised by P2X7 receptors. The P2X7-NLRP3 inflammasome axis has been identified as one of the main players in neuroinflammation. This study aimed to validate P2X7 receptors as therapeutic target for traumatic brain injury. Experimental approach: P2X7 receptors were studied by genetic and pharmacological approaches. Six non-nucleotide purine derivatives were evaluated as P2X7 antagonists. Compounds that prevented LPS + ATP-induced IL-1β release from primary glial cultures were investigated in the closed-head injury TBI model in vivo in male mice. Finally, we evaluated soluble (s)P2X7 receptor plasmatic levels in a cohort of TBI patients. Key results: P2rx7−/− mice showed an exaggerated inflammatory response 24 h post-TBI compared to control mice. However, animals treated with the selective P2X7 antagonist JNJ-47965567 (30 mg kg−1 i.p.) 30 min post-TBI showed improved neurological and inflammatory parameters. The purine derivative ITH15004 was the most potent compound reducing IL-1β production in vitro. When administered in vivo 30 min post-TBI, ITH15004 (1 mg kg−1 i.p.) improved both neuro-behavioural and inflammatory markers at 24 h. In TBI patients, we showed a tendency towards increase in circulating sP2X7 receptor levels at 24 and 72 h post-TBI. Conclusions and implications: These results highlight the importance of P2X7 receptors in the acute phase of TBI and present ITH15004 as a promising pharmacological tool to counteract P2X7 receptor-dependent neuroinflammation in vivo.
Docta Complutense
Publicación Artículo científico (JournalArticle)

The Role of P2X7 Receptor in Alzheimer’s Disease

  • Francistiová, Linda
  • Bianchi, Carolina
  • Di Lauro, Caterina
  • Sebastián Serrano, Álvaro
  • De Diego García, Laura
  • Kobolák, Julianna
  • Dinnyés, András
  • Díaz Hernández, Miguel
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized by a progressive cognitive decline associated with global brain damage. Initially, intracellular paired helical filaments composed by hyperphosphorylated tau and extracellular deposits of amyloid-b (Ab) were postulated as the causing factors of the synaptic dysfunction, neuroinflammation, oxidative stress, and neuronal death, detected in AD patients. Therefore, the vast majority of clinical trials were focused on targeting Ab and tau directly, but no effective treatment has been reported so far. Consequently, only palliative treatments are currently available for AD patients. Over recent years, several studies have suggested the involvement of the purinergic receptor P2X7 (P2X7R), a plasma membrane ionotropic ATP-gated receptor, in the AD brain pathology. In this line, altered expression levels and function of P2X7R were found both in AD patients and AD mouse models. Consequently, genetic depletion or pharmacological inhibition of P2X7R ameliorated the hallmarks and symptoms of different AD mouse models. In this review, we provide an overview of the current knowledge about the role of the P2X7R in AD.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Blockade of brain alkaline phosphatase efficiently reduces amyloid-β plaque burden and associated cognitive impairment

  • Soria Tobar, Lucía
  • Román Valero, Laura
  • Sebastián Serrano, Álvaro
  • Aivar, Paloma
  • Álvarez Castelao, Beatriz
  • Díaz Hernández, Miguel
Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease. Three new drugs for AD based on monoclonal antibodies against the amyloid-β peptide (Aβ) have recently been approved because they favor the reduction of the burden of senile plaque in the AD patient’s brain. Nonetheless, both drugs have very limited applicability and benefits and show several side effects. These limitations invite us to find alternative strategies for treating patients with AD. Here, we explored whether tissue-nonspecific alkaline phosphatase (TNAP), an ectoenzyme upregulated in the brain of AD patients and whose inhibition has beneficial effects on tau-induced pathology, is also efficient in reducing senile plaque burden. Methods: To evaluate whether TNAP may reduce cerebral senile plaque loading and Aβ-related toxicity, we use both pharmacological and genetic approaches. We analyze postmortem samples from human AD patients, APP/PS1 mice (a mouse model that mimics amyloid pathology observed in AD patients) treated or not with TNAP inhibitors, and the newly generated transgenic mouse line, TNAP-deficient APP/PS1 mice. Results: For the first time, we describe that genetic or pharmacological blockade of TNAP effectively reduces senile plaque burden by promoting its clearance, which leads to amelioration of cognitive impairment caused by Aβ-induced toxicity. These beneficial effects of TNAP inhibition occur concomitantly with higher microglial recruitment toward the senile plaque and increased microglial phagocytic capacity of Aβ by a mechanism involving metalloprotease-depending osteopontin processing. In addition, we also found that TNAP blockade favors LRP1-mediated transport of Aβ through the BBB. Conclusions: Here, we have shown that TNAP inhibition effectively reduces brain senile plaque burden and associated behavioral defects. Furthermore, given that we had previously reported that TNAP blockade also ameliorates Tau-induced neurotoxicity and increases lifespan of P301S tauopathy mouse model, we can state that TNAP blockade may be a novel and efficient therapy for treating patients with AD.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury

  • Valencia, Inés
  • Pastor-Martínez, Andrea
  • Decouty-Pérez, Céline
  • López-Rodriguez, Ana Belén
  • Álvarez-Rubal, María
  • Ramos Alonso, Eva
  • Calzaferri, Francesco
  • Zamorano-Fernández, Jorge
  • Giner-García, Javier
  • Palpán-Flores, Alexis J
  • Rodriguez-Dominguez, Victor
  • Rodríguez de Cía, Javier
  • Hernández-García, Borja J
  • Romero Martínez, Manuel Alejandro
  • De Los Rios, Cristobal
  • Egea, Javier
Background and purpose: Traumatic brain injury (TBI) is considered to be a leadingcause of mortality and disability worldwide. After TBI, innate immunity is rapidly acti-vated in response to damage-associated molecular patterns, such as ATP release,recognised by P2X7 receptors. The P2X7-NLRP3 inflammasome axis has been identi-fied as one of the main players in neuroinflammation. This study aimed to validateP2X7 receptors as therapeutic target for traumatic brain injury. Experimental approach: P2X7 receptors were studied by genetic and pharmacologi-cal approaches. Six non-nucleotide purine derivatives were evaluated as P2X7 antag-onists. Compounds that prevented LPS + ATP-induced IL-1β release from primaryglial cultures were investigated in the closed-head injury TBI model in vivo in malemice. Finally, we evaluated soluble (s)P2X7 receptor plasmatic levels in a cohort ofTBI patients. Key results: P2rx7 / mice showed an exaggerated inflammatory response 24 hpost-TBI compared to control mice. However, animals treated with the selective P2X7 antagonist JNJ-47965567 (30 mg kg 1 i.p.) 30 min post-TBI showed improvedneurological and inflammatory parameters. The purine derivative ITH15004 was themost potent compound reducing IL-1β production in vitro. When administered in vivo30 min post-TBI, ITH15004 (1 mg kg 1 i.p.) improved both neuro-behavioural andinflammatory markers at 24 h. In TBI patients, we showed a tendency towardsincrease in circulating sP2X7 receptor levels at 24 and 72 h post-TBI. Conclusions and implications: These results highlight the importance of P2X7 recep-tors in the acute phase of TBI and present ITH15004 as a promising pharmacologicaltool to counteract P2X7 receptor-dependent neuroinflammation in vivo.